1. Preclinical Characterization of AB-506, an Inhibitor of HBV Replication Targeting the Viral Core Protein. Mani, N., A.G. Cole, J.R. Phelps, A. Ardzinski, R. Burns, T. Chiu, A. Cuconati, B.D. Dorsey, E. Evangelista, K. Fan, F. Guo, T.O. Harasym, S. Kadhim, R. Kowalski, S.G. Kultgen, A.C.H. Lee, A.H. Li, S.A. Majeski, A. Miller, C. Pasetka, S.P. Reid, R. Rijnbrand, H.M. Micolochick Steuer, K. Stever, S. Tang, X. Teng, X. Wang, and M.J. Sofia. Antiviral Research, 2022. 197: 105211. PMID[34826506].
[PubMed]. HBV_01_2022.
Patent Citations
2. Preparation of Tricyclic Compounds Useful for the Treatment of HBV. Vendeville, S. Patent. 2022. 2021-17446651 20220000874: 102pp , Cont -in-part of U S Ser No 885,128.
[Patent]. HBV_01_2022.